This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The effectiveness of cannabis use in treating multiple sclerosis (MS) symptoms has been mixed. On the one hand, it has been shown to be effective in treating lower urinary tract symptoms1 as well as pain2 in these patients. In addition, significant numbers of patients with MS support the use of cannabis for symptom management.3,4 In contrast, other research has shown that cannabis use does not positively impact symptoms of spasticity.5 Two common MS sequelae for which the impact of cannabis use has not been systematically examined are cognitive and psychiatric problems. Such exploration is especially important given the known psychoactive properties of cannabis and its possible effect on cognition.
In this issue of Neurology®, Ghaffar and Feinstein6 report their evaluation of the cognitive and psychiatric consequences of cannabis use in patients with MS. The study presents interesting findings that make an important contribution to the MS literature. Specifically, the authors compared 10 patients with MS who reported smoking cannabis regularly (at least once per month) to …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.